Shinil Pharmaceutical

At a glance

Shinil Pharmaceutical filed 15 disclosures in the last 12 months, including 1 insider. The most recent key filing was on Jun 4.

Revenue for 2025 was ₩80.6B, down 9.9% on 2024. Operating margin was 9.2% against 17% a year earlier. Debt was 11% of equity at year end.

The 2025 annual report lists 413 employees with an average tenure of 6.9 years and average pay of ₩49.9M, #1455 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩226M each on average. It paid ₩190 per common share in cash dividends, against ₩190 a year earlier (+0%). 홍재현 and related parties held 32.58% at year end.

From the 2025 annual report

Staff: 413 (250 men, 163 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩20.6B. Directors and auditors: 5, paid ₩1.1B in total.

Dividends (common shares)

Largest shareholder

홍재현 holds 20.08%; with 22 related parties the group holds 32.58% of common shares at year end (from 32.73% at the start of the year).

Individuals paid ₩500M or more

Auditor: 인덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary